Adrecizumab-LPS Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
In this randomized, double-blind, placebo-controlled study, either a single dose of Adrecizumab (0.5, 2.0 or 8.0 mg/kg) or placebo will be administrated to 24 healthy male volunteers during experimental endotoxemia.
Epistemonikos ID: 3b40a60ea4b8684e6b0c4dcd20705ec6b156a779
First added on: May 20, 2024